Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial

Abstract

Given the clear benefit in disease-free survival, the low incidence of cardiac adverse events, and the suggestion that cardiac dysfunction might be reversible, adjuvant trastuzumab should be considered for treatment of breast cancer patients who fulfill the HERA trial eligibility criteria.